Category Archives: 2024
News link: A lymphoma survivor talks about his treatments with CAR T-cell therapy to fight cancer | Lymphoma Awareness Month – CBS Los Angeles
Irvine, CA, September 20, 2024 – A lymphoma survivor talks about his treatments with CAR T-cell therapy to fight cancer | Lymphoma Awareness Month – CBS Los Angeles, originally aired on September 19, 2024. To find the media clip … Continue reading
An article from City of Hope: Relapsed Lymphoma Patient Thrives After CAR T Cell Trial
Irvine, CA, September 20, 2024 – Relapsed Lymphoma Patient Thrives After CAR T Cell Trial – originally posted by City of Hope, on September 17, 2024. To find the article on the web: https://www.cityofhope.org/relapsed-lymphoma-patient-thrives-after-car-t-cell-trial About PMB-CT01 PMB-CT01 is … Continue reading
PeproMene Bio announced study demonstrating strong polyfunctionality of novel chimeric antigen receptor (CAR) T cells
IRVINE, Calif., Aug. 7, 2024 /PRNewswire/ — PeproMene Bio, Inc., a clinical-stage biotech company developing novel therapies for cancers and immune disorders, today announced that City of Hope-developed BAFF-R CAR T, known as PMB-CT01, demonstrated better polyfunctionality than CD19 CAR T cells, which are … Continue reading
PeproMene Bio, Inc. Announces Complete Remission of the Cohort 1 First Patient Treated for Relapsed and Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL) in the Phase 1 Clinical Trial of PMB-CT01 (BAFFR-CAR T Cells) at City of Hope
IRVINE, Calif., Jan. 18, 2024 /PRNewswire/ — PeproMene Bio, Inc., a clinical-stage biotech company developing novel therapies to treat cancers and immune disorders, today announced that the cohort 1 first patient treated in its Phase 1 relapsed or refractory B-cell acute lymphoblastic … Continue reading
